Payment overview · 2025
General Payments
$981.01
57 reported records · 12 companies
Healthcare provider profile · identity verified
Denis D Knight, DO
Allopathic & Osteopathic Physicians|Family Medicine · WICHITA, KS · NPI 1235190919
Verified facts
What the public records show
CMS Open Payments records show Denis D Knight, DO received $981.01 in general payments during 2025 across 57 reported records.
AstraZeneca Pharmaceuticals LP accounted for 19.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Kerendia, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Kerendia by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $189.16 | 19.3% | 11 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $157.26 | 16.0% | 10 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $137.07 | 14.0% | 9 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $108.73 | 11.1% | 6 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $100.25 | 10.2% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $93.23 | 9.5% | 5 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $78.61 | 8.0% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $29.34 | 3.0% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$26.57 | 2.7% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $23.82 | 2.4% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $21.30 | 2.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.67 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $960.79 | 56 |
| Education | $20.22 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $147.04 | 9 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $128.55 | 7 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $108.73 | 6 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $100.25 | 6 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $89.82 | 6 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $78.61 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $58.26 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $48.00 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $33.36 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $33.19 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $33.19 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $29.34 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $29.34 | 2 | 2025 |
Source payment records
|
|||||
| INTELLIS ADAPTIVESTIM Normalized: intellis adaptivestim |
Device | Medtronic, Inc. | $26.57 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $26.40 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $23.82 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $22.27 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $21.30 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $20.85 | 1 | 2025 |
Source payment records
|
|||||
| XHANCE Normalized: xhance |
Drug | Paratek Pharmaceuticals, Inc. | $20.27 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $15.67 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $15.67 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $12.61 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 63 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 48 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 101 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
55 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
63 | 16 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
101 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 672 | 135 |
| Levothyroxine Sodium | Levothyroxine Sodium | 519 | 107 |
| Eliquis | Apixaban | 461 | 42 |
| Gabapentin | Gabapentin | 459 | 74 |
| Amlodipine Besylate | Amlodipine Besylate | 366 | 89 |
| Potassium Chloride | Potassium Chloride | 320 | 63 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 299 | 63 |
| Omeprazole | Omeprazole | 279 | 58 |
| Lisinopril | Lisinopril | 274 | 65 |
| Losartan Potassium | Losartan Potassium | 269 | 66 |
| Pantoprazole Sodium | Pantoprazole Sodium | 227 | 57 |
| Trazodone Hcl | Trazodone Hcl | 219 | 32 |
| Tamsulosin Hcl | Tamsulosin Hcl | 212 | 45 |
| Furosemide | Furosemide | 210 | 50 |
| Metformin Hcl | Metformin Hcl | 208 | 46 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 193 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 177 | 40 |
| Clopidogrel | Clopidogrel Bisulfate | 158 | 30 |
| Zolpidem Tartrate | Zolpidem Tartrate | 150 | 27 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 147 | 39 |
| Donepezil Hcl | Donepezil Hcl | 139 | 25 |
| Allopurinol | Allopurinol | 137 | 24 |
| Carvedilol | Carvedilol | 135 | 30 |
| Buspirone Hcl | Buspirone Hcl | 132 | 22 |
| Metoprolol Succinate | Metoprolol Succinate | 132 | 33 |
| Memantine Hcl | Memantine Hcl | 129 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 123 | 25 |
| Simvastatin | Simvastatin | 123 | 32 |
| Escitalopram Oxalate | Escitalopram Oxalate | 115 | 24 |
| Famotidine | Famotidine | 113 | 21 |
| Mirtazapine | Mirtazapine | 108 | 23 |
| Sertraline Hcl | Sertraline Hcl | 104 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 101 | 27 |
| Ozempic | Semaglutide | 101 | 15 |
| Oxycodone Hcl | Oxycodone Hcl | 96 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 94 | 22 |
| Doxycycline Hyclate | Doxycycline Hyclate | 91 | 54 |
| Meloxicam | Meloxicam | 91 | 22 |
| Bumetanide | Bumetanide | 90 | 21 |
| Finasteride | Finasteride | 86 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 82 | 17 |
| Lorazepam | Lorazepam | 77 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 74 | 19 |
| Montelukast Sodium | Montelukast Sodium | 74 | 15 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 73 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 73 | 24 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 73 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 73 | 17 |
| Divalproex Sodium | Divalproex Sodium | 71 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 70 | 16 |
| Morphine Sulfate Er | Morphine Sulfate | 69 | 11 |
| Tramadol Hcl | Tramadol Hcl | 68 | 12 |
| Warfarin Sodium | Warfarin Sodium | 67 | suppressed |
| Estradiol | Estradiol | 63 | 11 |
| Farxiga | Dapagliflozin Propanediol | 63 | 16 |
| Alprazolam | Alprazolam | 62 | 16 |
| Bupropion Xl | Bupropion Hcl | 62 | 12 |
| Levetiracetam | Levetiracetam | 62 | suppressed |
| Ondansetron Odt | Ondansetron | 62 | 22 |
| Spironolactone | Spironolactone | 62 | 16 |
| Methocarbamol | Methocarbamol | 60 | suppressed |
| Novolog Flexpen | Insulin Aspart | 60 | 14 |
| Tradjenta | Linagliptin | 60 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 58 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 57 | 25 |
| Prednisone | Prednisone | 57 | 35 |
| Topiramate | Topiramate | 56 | suppressed |
| Ezetimibe | Ezetimibe | 55 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 55 | 14 |
| Metformin Hcl Er | Metformin Hcl | 55 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 55 | 15 |
| Vraylar | Cariprazine Hcl | 55 | suppressed |
| Clonazepam | Clonazepam | 54 | suppressed |
| Myrbetriq | Mirabegron | 53 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 51 | 12 |
| Jardiance | Empagliflozin | 48 | suppressed |
| Azithromycin | Azithromycin | 47 | 32 |
| Amitriptyline Hcl | Amitriptyline Hcl | 46 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 45 | 30 |
| Doxepin Hcl | Doxepin Hcl | 45 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 45 | 14 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 44 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 43 | 11 |
| Januvia | Sitagliptin Phosphate | 43 | suppressed |
| Glipizide Er | Glipizide | 42 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 42 | suppressed |
| Atenolol | Atenolol | 41 | suppressed |
| Baclofen | Baclofen | 41 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 41 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 41 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 41 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 41 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 40 | suppressed |
| Glimepiride | Glimepiride | 39 | suppressed |
| Sucralfate | Sucralfate | 39 | suppressed |
| Xarelto | Rivaroxaban | 39 | suppressed |
| Amantadine | Amantadine Hcl | 38 | suppressed |
| Fluconazole | Fluconazole | 35 | 18 |
| Haloperidol | Haloperidol | 35 | suppressed |
| Lactulose | Lactulose | 35 | suppressed |
| Aripiprazole | Aripiprazole | 34 | suppressed |
| Celecoxib | Celecoxib | 34 | 11 |
| Chlorthalidone | Chlorthalidone | 34 | suppressed |
| Ibuprofen | Ibuprofen | 34 | suppressed |
| Latanoprost | Latanoprost | 34 | 11 |
| Tresiba Flextouch U-100 | Insulin Degludec | 34 | suppressed |
| Pregabalin | Pregabalin | 32 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 32 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 31 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 30 | 11 |
| Prazosin Hcl | Prazosin Hcl | 30 | suppressed |
| Risperidone | Risperidone | 29 | suppressed |
| Acyclovir | Acyclovir | 28 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 28 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Cefdinir | Cefdinir | 28 | 23 |
| Meclizine Hcl | Meclizine Hcl | 28 | suppressed |
| Nystatin | Nystatin | 28 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 28 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 27 | suppressed |
| Naproxen | Naproxen | 27 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 27 | suppressed |
| Austedo | Deutetrabenazine | 26 | suppressed |
| Methylprednisolone | Methylprednisolone | 26 | 20 |
| Quetiapine Fumarate | Quetiapine Fumarate | 26 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 25 | suppressed |
| Budesonide | Budesonide | 25 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 15 |
| Sodium Chloride | 0.9 % Sodium Chloride | 24 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 23 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 22 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Cimetidine | Cimetidine | 21 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 21 | suppressed |
| Lamotrigine | Lamotrigine | 21 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 21 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 21 | suppressed |
| Primidone | Primidone | 21 | suppressed |
| Levofloxacin | Levofloxacin | 20 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 19 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 19 | suppressed |
| Premarin | Estrogens, Conjugated | 19 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Metronidazole | Metronidazole | 18 | suppressed |
| Calcium Acetate | Calcium Acetate | 17 | suppressed |
| Fentanyl | Fentanyl | 17 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Novofine Autocover | Pen Needle, Diabetic, Safety | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 17 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 17 | suppressed |
| Trulicity | Dulaglutide | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 16 | suppressed |
| Scopolamine | Scopolamine | 16 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 15 | suppressed |
| Carisoprodol | Carisoprodol | 15 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 15 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Entresto | Sacubitril/Valsartan | 14 | suppressed |
| Kerendia | Finerenone | 14 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 14 | suppressed |
| Metolazone | Metolazone | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 14 | suppressed |
| Clozapine | Clozapine | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 13 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 13 | suppressed |
| Sotalol | Sotalol Hcl | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 13 | suppressed |
| Trospium Chloride Er | Trospium Chloride | 13 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 12 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 12 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Renvela | Sevelamer Carbonate | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Carbamazepine Er | Carbamazepine | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Quviviq | Daridorexant Hcl | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $981.01 · 57 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, Auvelity, BREZTRI, CAPLYTA, EVENITY, FARXIGA, FREESTYLE LIBRE 3, INTELLIS ADAPTIVESTIM, JARDIANCE, KISUNLA, Kerendia, MOUNJARO, NUZYRA, Ozempic, PROLIA, QULIPTA, Rybelsus, SHINGRIX, UBRELVY, Wegovy, XHANCE, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error